Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)

Market Cap	37.89B
Revenue (ttm)	6.13B
Net Income (ttm)	1.48B
Shares Out	1.98B
EPS (ttm)	0.74
PE Ratio	25.95
Forward PE	22.39
Dividend	0.10 (0.52%)
Ex-Dividend Date	Jun 20, 2024

Volume	14,052,559
Average Volume	25,312,212
Open	19.18
Previous Close	19.16
Day's Range	19.11 - 19.25
52-Week Range	18.88 - 27.60
Beta	0.65
RSI	34.35
Earnings Date	Aug 26, 2025

About SHA:600161

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for inje...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1966
• Employees: 5,298
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600161

Financial Performance

In 2024, SHA:600161's revenue was 6.03 billion, an increase of 16.44% compared to the previous year's 5.18 billion. Earnings were 1.55 billion, an increase of 39.58%.